STEP 1 (N = 1,961 adults with obesity, no diabetes): Semaglutide 2.4 mg weekly vs placebo 68-week treatment duration Mean weight loss: 14.9% of baseline body weight (semaglutide) vs 2.4% (placebo) 86% of semaglutide patients lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Published in New England Journal of Medicine, 2021 (Wilding et al.) STEP 2 (N = 1,210 adults with obesity and type 2 diabetes): Semaglutide 2.4 mg vs 1 mg vs placebo 68-week duration Mean weight loss: 9.6% (2.4 mg dose) vs 7.0% (1 mg dose) vs 3.4% (placebo) Diabetes patients lose less weight than non-diabetic patients on the same dose, likely due to baseline insulin resistance Published in Lancet, 2021 (Davies et al.) STEP 3 (N = 611, semaglutide plus intensive behavioral therapy): Mean weight loss: 16.0% at 68 weeks Adding structured diet and exercise counseling improved outcomes by approximately 1% absolute weight loss vs medication alone STEP 4 (withdrawal study, N = 803): Patients who achieved weight loss on semaglutide were randomized to continue semaglutide vs switch to placebo Patients who continued semaglutide lost an additional 7.9% of body weight over 48 weeks Patients switched to placebo regained 6.9% of body weight This demonstrates that semaglutide requires ongoing treatment
A 3 g/day crystalline formulation for 4 weeks achieved clinical and endoscopic remission in 65% of patients [525], compared to 20% with placebo, while the low-dose 450 mg/day was ineffective [525]
Oral 8.2.1.1 Mouse 8.2.1.2 Rat 8.2.1.3 Rabbit 8.2.1.4 Cat 8.2.1.5 Dog 8.2.1.6 Pig 8.2.1.7 Cow 8.2.2
Common side effects include nausea, stomach upset, diarrhea , and a fishy body odor , especially at higher doses
Targeted bisulfite sequencing for biomarker discovery
.webp)
